PTEN (Phosphatase and Tensin Homolog Deleted on Chromosome 10) is a critical tumor suppressor protein that negatively regulates the PI3K/AKT signaling pathway, playing essential roles in neuronal survival, synaptic plasticity, and cellular homeostasis[1]. In the context of neurodegenerative diseases, PTEN dysregulation contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease through its effects on cell death pathways, protein homeostasis, and metabolic regulation[2].
PTEN was originally identified as a tumor suppressor gene located on chromosome 10q23, frequently deleted in various cancers. However, subsequent research revealed its crucial functions in the nervous system, where it regulates fundamental processes including neuronal development, synaptic plasticity, and cell survival[3].
| PTEN Protein | |
|---|---|
| Full Name | Phosphatase and Tensin Homolog |
| Gene | [PTEN](/genes/pten) (10q23.3) |
| UniProt ID | [P60484](https://www.uniprot.org/uniprot/P60484) |
| Protein Size | 403 amino acids (~47 kDa) |
| Protein Family | PTEN-like phosphatase family |
| Subcellular Location | Cytoplasm, nucleus, plasma membrane |
| Associated Diseases | AD, PD, ALS, HD, brain tumors |
PTEN is a 403 amino acid protein with a molecular weight of approximately 47.2 kDa. The protein contains several distinct structural domains[4]:
| Domain | Amino Acids | Function |
|---|---|---|
| Phosphatase domain | 14-185 | Catalytic phosphatase activity |
| C2 domain | 186-351 | Membrane phospholipid binding |
| C-terminal tail | 352-403 | Regulatory functions, protein interactions |
The N-terminal phosphatase domain contains the active site motif HCXXGRXXR, which is essential for PTEN's enzymatic activity. This domain:
The C2 domain mediates membrane association through phospholipid binding:
The C-terminal region contains:
PTEN activity is regulated by several post-translational modifications[5]:
The PI3K/AKT signaling pathway is one of the most critical survival pathways in neurons[6]:
The pathway components include:
In neurons, PTEN plays several critical roles [7][8]:
PTEN maintains cellular homeostasis by:
PTEN dysregulation contributes to multiple aspects of AD pathogenesis [10][11][12]:
Amyloid-beta effects: Aβ oligomers stimulate PTEN translocation to synapses, where it:
Tau pathology: PTEN/AKT/GSK3β dysregulation:
Therapeutic implications: PTEN inhibitors are being explored for AD treatment to:
In PD, PTEN plays complex roles in dopaminergic neuron survival [13][14]:
α-Synuclein interaction: PTEN may be involved in:
Mitochondrial dysfunction: PTEN:
Dopaminergic neuron vulnerability: PTEN may contribute to selective vulnerability through:
PTEN dysregulation in ALS includes [15]:
Motor neuron degeneration: PTEN promotes motor neuron death through:
TDP-43 pathology: Connections between PTEN and TDP-43:
Therapeutic targeting: PTEN inhibition may protect motor neurons in ALS
In HD, mutant huntingtin affects PTEN signaling [16]:
mHTT effects: Mutant huntingtin:
Therapeutic strategies: Modulating PTEN/AKT balance may:
Several strategies are being developed to target PTEN [17][18]:
| Strategy | Compound | Status | Mechanism |
|---|---|---|---|
| PTEN inhibitors | VO-OHpic | Preclinical | Phosphate binding site blockade |
| PTEN inhibitors | SF1670 | Preclinical | Oxidative PTEN inhibition |
| PTEN inhibitors | BZLF1 | Research | E3 ligase modulation |
| PTEN modulators | Diphenyl difluoroketone | Preclinical | PTEN degradation |
| AKT activators | SC79 | Preclinical | Direct AKT activation |
Alternative approaches include direct AKT activation:
Challenges in targeting PTEN for neurodegeneration:
| Biomarker | Sample | Significance |
|---|---|---|
| PTEN expression | Brain tissue | Reduced in AD/PD brains |
| p-AKT/AKT ratio | CSF/blood | Decreased with PTEN overactivity |
| p-GSK3β/GSK3β | Brain tissue | Increased with PTEN dysregulation |
| PIP3 levels | Cell models | Reduced with PTEN hyperactivity |
PTEN biomarkers may predict:
PTEN intersects with multiple neurodegenerative pathways [5:1]:
Rodgers SJ, O'Neill MT, Lackovic J, et al. "PTEN in the nervous system: insights into behaviour and disease." Journal of Neurochemistry. Journal of Neurochemistry. 2021. ↩︎
Tandon A, Uversky VN. "The role of PTEN in neurodegeneration." Molecular Neurobiology. Molecular Neurobiology. 2019. ↩︎
Howitt J, Lackovic J, Low LH, et al. "PTEN in neurobiology." Current Alzheimer Research. Current Alzheimer Research. 2012. ↩︎
Lee JO, Yang H, Georgescu MM, et al. "Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association." Cell. Cell. 1999. ↩︎
Jiang Q, Wang Y, Shi X, et al. "PTEN in neurodegeneration: networking with multiple pathways." Cellular and Molecular Life Sciences. Cellular and Molecular Life Sciences. 2021. ↩︎ ↩︎
Yuen T, Tseng WW, Nwankwo C, et al. "PTEN in the nervous system." Brain Research. Brain Research. 2019. ↩︎
Skeberdis VA, Lan J, Zheng X, et al. "Insulin-like growth factor I protects against excitotoxicity through the PI3K/Akt pathway." Journal of Neuroscience. Journal of Neuroscience. 2011. ↩︎
Jia S, Liu Z, Zhang S, et al. "PTEN signaling in synaptic plasticity and memory." Nature Reviews Neuroscience. Nature Reviews Neuroscience. 2020. ↩︎
Javaid N, Choi S. "mTOR-mediated regulation of autophagy and neurodegeneration." Cells. Cells. 2023. ↩︎
Chuang DM, Wang Z, Chiu CT. "GSK-3 as a target for lithium neuroprotection." Neuropsychiatric Disease and Treatment. Neuropsychiatric Disease and Treatment. 2011. ↩︎
Ksiezak-Roding H, Perier C. "The role of PTEN in Alzheimer's disease." Journal of Alzheimer's Disease. Journal of Alzheimer's Disease. 2018. ↩︎
Zhang L, Zhang Z, Chen F, et al. "AKT signaling in neuronal survival and neurodegenerative diseases." Frontiers in Cellular Neuroscience. Frontiers in Cellular Neuroscience. 2023. ↩︎
Zhou X, Zhou J, Li L, et al. "PTEN in Parkinson's disease." Neurobiology of Disease. Neurobiology of Disease. 2019. ↩︎
Hatano Y, Li Y, Sato K, et al. "PTEN mutations in familial Parkinson's disease." Brain. Brain. 2019. ↩︎
Yoshimura M, Ichikawa M, Shinauti A, et al. "PTEN and ALS." Acta Neuropathologica. Acta Neuropathologica. 2018. ↩︎
Wu J, Liu W, Bode B, et al. "PTEN and Huntington's disease." Human Molecular Genetics. Human Molecular Genetics. 2015. ↩︎
Rosivatz E, Matthews JG, McDonald NQ, et al. "A small molecule inhibitor of PTEN." Chemistry & Biology. Chemistry & Biology. 2006. ↩︎
Mak LH, Woscholski R. "Targeting PTEN using small molecule inhibitors." Biochemical Society Transactions. Biochemical Society Transactions. 2013. ↩︎